Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation.

@article{Cappato2014RivaroxabanVV,
  title={Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation.},
  author={Riccardo Cappato and Michael D. Ezekowitz and Allan L. Klein and A. John Camm and Chang-Sheng Ma and Jean-Yves le Heuzey and Mario Talajic and Mauricio Ibrahim Scanavacca and Panos E. Vardas and Paulus Kirchhof and Melanie Hemmrich and Vivian Lanius and Isabelle Ling Meng and Peter Wildgoose and Martin van Eickels and Stefan H. Hohnloser},
  journal={European heart journal},
  year={2014},
  volume={35 47},
  pages={
          3346-55
        }
}
AIMS X-VeRT is the first prospective randomized trial of a novel oral anticoagulant in patients with atrial fibrillation undergoing elective cardioversion. METHODS AND RESULTS We assigned 1504 patients to rivaroxaban (20 mg once daily, 15 mg if creatinine clearance was between 30 and 49 mL/min) or dose-adjusted vitamin K antagonists (VKAs) in a 2:1 ratio. Investigators selected either an early (target period of 1-5 days after randomization) or delayed (3-8 weeks) cardioversion strategy. The… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 151 CITATIONS, ESTIMATED 42% COVERAGE

NOACs and atrial fibrillation: Incidence and predictors of left atrial thrombus in the real world.

  • International journal of cardiology
  • 2017
VIEW 13 EXCERPTS
CITES METHODS, BACKGROUND & RESULTS
HIGHLY INFLUENCED

Severe Spontaneous Echo Contrast/Auricolar Thrombosis in "Nonvalvular" AF: Value of Thromboembolic Risk Scores.

  • Pacing and clinical electrophysiology : PACE
  • 2017
VIEW 7 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Cardioversion of atrial fibrillation in a real-world setting: non-vitamin K antagonist oral anticoagulants ensure a fast and safe strategy compared to warfarin.

  • Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
  • 2018
VIEW 5 EXCERPTS
CITES RESULTS & METHODS
HIGHLY INFLUENCED

Outcomes after catheter ablation and cardioversion in patients with non-valvular atrial fibrillation: results from the prospective, observational XANTUS study.

  • Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
  • 2018
VIEW 5 EXCERPTS
CITES RESULTS & BACKGROUND

Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT trial.

  • Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
  • 2016
VIEW 7 EXCERPTS
CITES RESULTS, BACKGROUND & METHODS

Möglichkeiten und Herausforderungen in der oralen Antikoagulation

oralen Antikoagulation, Miklos Rohla
  • 2019
VIEW 5 EXCERPTS
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2012
2019

CITATION STATISTICS

  • 13 Highly Influenced Citations

  • Averaged 25 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 14 REFERENCES